Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction In Patients With Resistant Hypertension and Type 2 Diabetes Mellitus

Aim      To study the incidence and clinical and pathophysiological features of diastolic dysfunction (DD) and chronic heart failure with preserved ejection fraction (HFpEF) in patients with resistant arterial hypertension (RAH) associated with type 2 diabetes mellitus (DM).

Material and methods  A cross-sectional study that included 36 patients with RAH associated with type 2 DM (mean age, 61.4±6.4 years; 14 men) was performed. Measurement of office and 24-h blood pressure (BP), standard echocardiography with assessment of diastolic function (DF) and ventricular-arterial coupling, doppler ultrasound imaging of renal blood flow, and laboratory tests (blood glucose, glycated hemoglobin, blood creatinine, tumor necrosis factor α (TNF-α), brain natriuretic peptide (BNP), type 2 and type 9 matrix metalloproteinases (MMP-2 and MMP-9), tissue inhibitor of MMP 1 (TIMP-1), 24-h urine protein test, and 24-h urine volume test were performed for all patients. HFpEF was diagnosed according to criteria of the American Society of Echocardiography and the European Society of Cardiology 2019, and the Russian Clinical Guidelines on Diagnosis and Treatment of CHF 2017 and 2020.

Results All patients had DD. Incidence of HFpEF detection according to the Russian Guidelines 2017 was 100%; according to the Russian Guidelines 2020, that included a required increase in BNP, and according to the criteria of the European Guidelines 2019, this incidence was 89 %. In 55.6 % of patients, DD corresponded to grade 2 (pseudonormal type). According to the correlation analysis, the DF impairment was associated with increases in pulse BP, myocardial mass, arterial and left ventricular elastance (arterial wall and left ventricular elasticity), basal glycemia and DM duration, MMP-2 level, proteinuria, blood creatinine, renal vascular resistance, and also with decreases in 24-h urine volume, MMP-9, TIMP-1, and TIMP-1/MMP-2. Significance of the relations of mean E / e’ ratio with nighttime pulse BP, MMP-9, and 24-h urine volume were confirmed by results of multiple linear regression analysis. Increased myocardial and vascular wall stiffness, concentrations of MMP-2 and TNF-α and reduced 24-h urine volume were associated with progressive impairment of DF.

Conclusion      The combination of RAH and DM-2 is characterized by an extremely high incidence of DD that determines a great prevalence of HFpEF. The development and progression of DD in such patients are closely related with a complex of metabolic, proinflammatory and profibrotic biomarkers, increased vascular wall stiffness, pronounced left ventricular hypertrophy, and with structural and functional alterations in kidneys.

1. Kosmala W, Marwick TH. Asymptomatic Left Ventricular Diastolic Dysfunction: Predicting Progression to Symptomatic Heart Failure. JACC Cardiovasc Imaging.2020; 13(1Pt2):215-227. DOI:10.1016/j.jcmg.2018.10.039

2. Savji, N., Meijers, W. C., Bartz, T. M., Bhambhani, V., Cushman, M., Nayor, M. et al. The association of obesity and cardiometabolic traits with incident HFpEF and HFrEF. JACC: Heart Failure. 2018; 6(8), 701-709. DOI:10.1016/j.jchf.2018.05.018

3. Zhang W, Liu CY, Ji LN, Wang JG; ATTEND investigators. Blood pressure and glucose control and the prevalence of albuminuria and left ventricular hypertrophy in patients with hypertension and diabetes. J Clin Hypertens (Greenwich). 2020; 22(2):212-220. DOI: 10.1111/jch.13793

4. Pieske, B., Tschöpe, C., De Boer, R. A., Fraser, A. G., Anker, S. D., Donal, E. et al. How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019; 40: 3297–3317. DOI:10.1093/eurheartj/ehz641

5. Mareev V.Yu., Fomin I.V., Ageev F.T., Begrambekova Yu.L., Vasyuk Yu.A., Garganeeva A.A. et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatmen. Kardiologiia. 2018; 58 (6S): 8–164. [Russian: Мареев В.Ю., Фомин И.В., Агеев Ф.Т., Беграмбекова Ю.Л., Васюк Ю.А., Гарганеева А.А. и др. Клинические рекомендации ОССН – РКО – РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология.2018; 58(6S):8- 164]. DOI: 10.18087/cardio.2475

6. Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020; 25(11):4083. [Russian: Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4083:]. DOI:10.15829/1560-4071-2020-4083

7. Nagueh, S. F., Smiseth, O. A., Appleton, C. P., Byrd, B. F., 3rd, Dokainish, H., Edvardsen, T. et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography: official publication of the American Society of Echocardiography.2016; 29(4), 277–314. DOI: 10.1016/j.echo.2016.01.011

8. Naqvi TZ. Diastolic function assessment incorporating new techniques in Doppler echocardiography. Rev Cardiovasc Med. 2003 Spring;4(2):81-99. PMID: 12776017

9. Chen CH, Fetics B, Nevo E, Rochitte CE, Chiou KR, Ding PA et al. Noninvasive single-beat determination of left ventricular end-systolic elastance in humans. J Am Coll Cardiol. 2001; 38(7):2028-34. DOI: 10.1016/s0735-1097(01)01651-5

10. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020; 25(3):3786. [Russian:Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):3786]. DOI:10.15829/1560-4071-2020-3-3786

11. Bouthoorn, S., Valstar, G. B., Gohar, A., den Ruijter, H. M., Reitsma, H. B., Hoes, A. W. et al. The prevalence of left ventricular diastolic dysfunction and heart failure with preserved ejection fraction in men and women with type 2 diabetes: A systematic review and meta-analysis. Diabetes & vascular disease research.2018; 15(6), 477–493. DOI: 10.1177/1479164118787415

12. Nadruz W, Shah AM., Solomon SD. Diastolic Dysfunction and Hypertension. Surg Clin North Am.2017; 101(1): 7–17. DOI:10.1016/j.mcna.2016.08.013

13. Jin CN, Liu M, Sun JP, Fang F, Wen YN, Yu CM et al. The prevalence and prognosis of resistant hypertension in patients with heart failure. PLoS One. 2014;9(12):e114958. DOI: 10.1371/journal.pone.0114958

14. Mareev Yu.V., Garganeeva A.A., Tukish O.V., Rebrova T.Yu., Anikina D.V., Mareev V.Yu. Difficulties in diagnosis of heart failure with preserved ejection fraction in clinical practice: dissonance between echocardiography, NTproBNP and H2HFPEF score. Kardiologiia. 2019;59(12S):37-45. [Russian: Мареев Ю.В., Гарганеева А.А., Тукиш О.В., Реброва Т.Ю., Аникина Д.В., Мареев В.Ю. Сложности в диагностике сердечной недостаточности с сохраненной фракцией выброса в реальной клинической практике: диссонанс между клиникой, эхокардиографическими изменениями, величиной натрийуретических пептидов и шкалой H2FPEF. Кардиология. 2019;59(12S):37-45.]. DOI:10.18087/cardio.n695

15. Anjan VY, Loftus TM, Burke MA, Akhter N, Fonarow GC, Gheorghiade M et al. Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction. Am J Cardiol. 2012; 110(6):870-6. DOI: 10.1016/j.amjcard.2012.05.014

16. Obokata M, Kane GC, Reddy YNV, Olson TP, Melenovsky V, Borlaug BA. Role of Diastolic Stress Testing in the Evaluation for Heart Failure with Preserved Ejection Fraction: A Simultaneous Invasive- Echocardiographic Study. Circulation.2017; 135(9):825–38. DOI:10.1161/CIRCULATIONAHA.116.024822

17. Buckley LF, Canada JM, Del Buono MG, Carbone S, Trankle CR, Billingsley H et al. Low NT-proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction. ESC Heart Fail. 2018 Apr;5(2):372-378. DOI: 10.1002/ehf2.12235

18. de Boer R.A., De Keulenaer G., Bauersachs J., Brutsaert D., Cleland J.G., Diez J. et al. Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. Eur. J. Heart Fail. 2019; 21:272–285. DOI: 10.1002/ejhf.1406

19. Di Nicolò P, Granata A. Renal intraparenchymal resistive index: the ultrasonographic answer to many clinical questions. J Nephrol. 2019;32(4):527-538. DOI: 10.1007/s40620-018-00567-x

20. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation. 2006;113(17):2089-6. DOI:10.1161/CIRCULATIONAHA.105.573865.

21. Kuzuya M, Nakamura K, Sasaki T, Cheng XW, Itohara S, Iguchi A. Effect of MMP-2 deficiency on atherosclerotic lesion formation in apoE-deficient mice. Arterioscler Thromb Vasc Biol. 2006; 26(5):1120-5. DOI: 10.1161/01.ATV.0000218496.60097.e0

22. Johnson JL, George SJ, Newby AC, Jackson CL. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci U S A. 2005; 102(43):15575-80. DOI: 10.1073/pnas.0506201102

23. Chavey C, Mari B, Monthouel MN, Bonnafous S, Anglard P, Van Obberghen E et al. Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation. J Biol Chem. 2003; 278(14):11888-96. DOI: 10.1074/jbc.M209196200

24. Dunlay S. M., Weston S. A., Redfield M. M., Killian J. M., Roger V́. L. Tumor Necrosis Factor-α and Mortality in Heart Failure. Circulation. 2008; 118(6):625–631.DOI: 10.1161/CIRCULATIONAHA.107.759191

25. Mocan M, Mocan Hognogi LD, Anton FP, Chiorescu RM, Goidescu CM, Stoia MA et al. Biomarkers of Inflammation in Left Ventricular Diastolic Dysfunction. Dis Markers. 2019; 2019:7583690. DOI: 10.1155/2019/7583690.

26. Dinh W, Füth R, Nickl W, Krahn T, Ellinghaus P, Scheffold T et al. Elevated plasma levels of TNF-alpha and interleukin-6 in patients with diastolic dysfunction and glucose metabolism disorders. Cardiovasc Diabetol. 2009; 8:58. DOI: 10.1186/1475-2840-8-58

27. Liu JH, Chen Y, Yuen M, Zhen Z, Chan CW, Lam KS et al. Incremental prognostic value of global longitudinal strain in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2016; 15:22. DOI: 10.1186/s12933-016-0333-5.

28. Blomstrand P, Engvall M, Festin K, Lindström T, Länne T, Maret E et al. Left ventricular diastolic function, assessed by echocardiography and tissue Doppler imaging, is a strong predictor of cardiovascular events, superior to global left ventricular longitudinal strain, in patients with type 2 diabetes. Eur Heart J Cardiovasc Imaging. 2015; 16(9):1000-7. DOI: 10.1093/ehjci/jev027.

29. Falkovskaya A.Yu., Mordovin V.F., Pekarskiy S.E., Ripp T.M., Manukyan M.A., Lichikaki V.A., Sitkova E.S., Zyubanova I.V., Gusakova A.M., Baev A.E., Ryabova T.R., Ryumshina N.I. Renal denervation as a new nephroprotective strategy in diabetic patients with resistant hypertension. The Siberian Journal of Clinical and Experimental Medicine. 2020; 35(1):80-92. [Russian: Фальковская А.Ю., Мордовин В.Ф., Пекарский С.Е., Рипп Т.М., Манукян М.А., Личикаки В.А., Ситкова Е.С., Зюбанова И.В., Гусакова А.М., Баев А.Е., Рябова Т.Р., Рюмшина Н.И. Ренальная денервация как новая стратегия нефропротекции у больных резистентной артериальной гипертонией, ассоциированной с сахарным диабетом 2-го типа. Сибирский журнал клинической и экспериментальной медицины. 2020;35(1):80-92]. DOI: 10.29001/2073-8552-2020-35-1-80-92